Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to -$6.2 million.

  • Ani Pharmaceuticals' Cash from Investing Activities rose 9845.35% to -$6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.6 million, marking a year-over-year increase of 8906.79%. This contributed to the annual value of -$404.7 million for FY2024, which is 208637.03% down from last year.
  • Ani Pharmaceuticals' Cash from Investing Activities amounted to -$6.2 million in Q3 2025, which was up 9845.35% from -$6.9 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Cash from Investing Activities high stood at $8.9 million for Q1 2024, and its period low was -$398.5 million during Q3 2024.
  • Its 5-year average for Cash from Investing Activities is -$30.4 million, with a median of -$4.8 million in 2023.
  • Data for Ani Pharmaceuticals' Cash from Investing Activities shows a peak YoY increase of 47964.3% (in 2024) and a maximum YoY decrease of 865295.41% (in 2024) over the last 5 years.
  • Over the past 5 years, Ani Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$82.2 million in 2021, then soared by 96.18% to -$3.1 million in 2022, then crashed by 52.1% to -$4.8 million in 2023, then plummeted by 123.5% to -$10.7 million in 2024, then soared by 42.3% to -$6.2 million in 2025.
  • Its last three reported values are -$6.2 million in Q3 2025, -$6.9 million for Q2 2025, and -$19.8 million during Q1 2025.